piracetam has been researched along with Multiple Sclerosis, Chronic Progressive in 1 studies
Piracetam: A compound suggested to be both a nootropic and a neuroprotective agent.
Multiple Sclerosis, Chronic Progressive: A form of multiple sclerosis characterized by a progressive deterioration in neurologic function which is in contrast to the more typical relapsing remitting form. If the clinical course is free of distinct remissions, it is referred to as primary progressive multiple sclerosis. When the progressive decline is punctuated by acute exacerbations, it is referred to as progressive relapsing multiple sclerosis. The term secondary progressive multiple sclerosis is used when relapsing remitting multiple sclerosis evolves into the chronic progressive form. (From Ann Neurol 1994;36 Suppl:S73-S79; Adams et al., Principles of Neurology, 6th ed, pp903-914)
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate the effects of levetiracetam, an antiepileptic drug, on tremor severity and related functionality in MS." | 9.14 | The effect of levetiracetam on tremor severity and functionality in patients with multiple sclerosis. ( D'hooghe, MB; Feys, P; Helsen, WF; Nagels, G, 2009) |
| "To investigate the effects of levetiracetam, an antiepileptic drug, on tremor severity and related functionality in MS." | 5.14 | The effect of levetiracetam on tremor severity and functionality in patients with multiple sclerosis. ( D'hooghe, MB; Feys, P; Helsen, WF; Nagels, G, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Feys, P | 1 |
| D'hooghe, MB | 1 |
| Nagels, G | 1 |
| Helsen, WF | 1 |
1 trial available for piracetam and Multiple Sclerosis, Chronic Progressive
| Article | Year |
|---|---|
The effect of levetiracetam on tremor severity and functionality in patients with multiple sclerosis.
Topics: Administration, Oral; Adult; Anticonvulsants; Cross-Over Studies; Dose-Response Relationship, Drug; | 2009 |